Pancreatic iron and glucose dysregulation in thalassemia major

American Journal of Hematology

Volumn 87, Issue 2, 2012, Pages 155-160

  Noetzli, Leila J ^a   Mittelman, Steven D ^a   Watanabe, Richard M ^b   Coates, Thomas D ^a   Wood, John C ^a  

^a CHILDREN S HOSPITAL LOS ANGELES   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEFERASIROX; DEFERIPRONE; GLUCOSE; IRON;

ADOLESCENT; ADULT; AGE; ANALYTICAL PARAMETERS; ARTICLE; CHILD; CYTOTOXICITY; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE MARKER; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; GLYCEMIC CONTROL; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; IRON OVERLOAD; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL MODEL; NUCLEAR MAGNETIC RESONANCE IMAGING; ORAL GLUCOSE TOLERANCE TEST; PANCREAS FUNCTION; PANCREAS IRON LEVEL; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; SCHOOL CHILD; THALASSEMIA MAJOR;

ADOLESCENT; ADULT; BETA-THALASSEMIA; BLOOD TRANSFUSION; CHILD; DIABETES MELLITUS; FEMALE; GLUCOSE; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; HUMANS; INSULIN; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; IRON; IRON OVERLOAD; LIVER; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MYOCARDIUM;

EID: 84855977812     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.22223     Document Type: Article

References (44)

1. Modell B, Khan M, Darlison M. Survival in beta-thalassaemia major in the UK: Data from the UK Thalassaemia Register. Lancet 2000; 355: 2051-2052.
2. Chouliaras G, Berdoukas V, Ladis V, et al. Impact of magnetic resonance imaging on cardiac mortality in thalassemia major. J Magn Reson Imaging 2011; 34: 56-59.
3. Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica 2004; 89: 1187-1193.
4. Vogiatzi MG, Macklin EA, Trachtenberg FL, et al. Differences in the prevalence of growth, endocrine and vitamin D abnormalities among the various thalassaemia syndromes in North America. Br J Haematol 2009; 146: 546-556.
5. Angelopoulos NG, Zervas A, Livadas S, et al. Reduced insulin secretion in normoglycaemic patients with beta-thalassaemia major. Diabet Med 2006; 23: 1327-1331.
6. Cario H, Holl RW, Debatin KM, et al. Insulin sensitivity and beta-cell secretion in thalassaemia major with secondary haemochromatosis: Assessment by oral glucose tolerance test. Eur J Pediatr 2003; 162: 139-146.
7. Messina MF, Lombardo F, Meo A, et al. Three-year prospective evaluation of glucose tolerance, beta-cell function and peripheral insulin sensitivity in non-diabetic patients with thalassemia major. J Endocrinol Invest 2002; 25: 497-501.
8. Siklar Z, Citak FE, Uysal Z, et al. Evaluation of glucose homeostasis in transfusion-dependent thalassemic patients. Pediatr Hematol Oncol 2008; 25: 630-637.
9. Jaruratanasirikul S, Chareonmuang R, Wongcharnchailert M, et al. Prevalence of impaired glucose metabolism in beta-thalassemic children receiving hypertransfusions with a suboptimal dosage of iron-chelating therapy. Eur J Pediatr 2008; 167: 873-876.
10. Hafez M, Youssry I, El-Hamed FA, et al. Abnormal glucose tolerance in beta-thalassemia: Assessment of risk factors. Hemoglobin 2009; 33: 101-108.
11. Merkel PA, Simonson DC, Amiel SA, et al. Insulin resistance and hyperinsulinemia in patients with thalassemia major treated by hypertransfusion. N Engl J Med 1988; 318: 809-814.
12. Tsapas A, Vlachaki E, Christoforidis A, et al. Insulin sensitivity assessment with euglycemic insulin clamp in adult beta-thalassaemia major patients. Eur J Haematol 2007; 79: 526-530.
13. Dmochowski K, Finegood DT, Francombe W, et al. Factors determining glucose tolerance in patients with thalassemia major. J Clin Endocrinol Metab 1993; 77: 478-483.
14. Cavallo-Perin P, Pacini G, Cerutti F, et al. Insulin resistance and hyperinsulinemia in homozygous beta-thalassemia. Metabolism 1995; 44: 281-286.
15. Chern JP, Lin KH, Lu MY, et al. Abnormal glucose tolerance in transfusion-dependent beta-thalassemic patients. Diabetes Care 2001; 24: 850-854.
16. Mowla A, Karimi M, Afrasiabi A, et al. Prevalence of diabetes mellitus and impaired glucose tolerance in beta-thalassemia patients with and without hepatitis C virus infection. Pediatr Endocrinol Rev 2004; 2( Suppl 2): 282-284.
17. Sougleri M, Labropoulou-Karatza C, Paraskevopoulou P, et al. Chronic hepatitis C virus infection without cirrhosis induces insulin resistance in patients with alpha-thalassaemia major. Eur J Gastroenterol Hepatol 2001; 13: 1195-1199.
18. Pappas S, Donohue SM, Denver AE, et al. Glucose intolerance in thalassemia major is related to insulin resistance and hepatic dysfunction. Metabolism 1996; 45: 652-657.
19. Au WY, Lam WM, Chu WC, et al. A magnetic resonance imaging study of iron overload in hemopoietic stem cell transplant recipients with increased ferritin levels. Transplant Proc 2007; 39: 3369-3374.
20. Matter RM, Allam KE, Sadony AM. Gradient-echo magnetic resonance imaging study of pancreatic iron overload in young Egyptian beta-thalassemia major patients and effect of splenectomy. Diabetol Metab Syndr 2010; 2: 23.
21. Papakonstantinou O, Ladis V, Kostaridou S, et al. The pancreas in beta-thalassemia major: MR imaging features and correlation with iron stores and glucose disturbances. Eur Radiol 2007; 17: 1535-1543.
22. Oudit GY, Trivieri MG, Khaper N, et al. Role of L-type Ca2+ channels in iron transport and iron-overload cardiomyopathy. J Mol Med 2006; 84: 349-364.
23. Anderson LJ, Westwood MA, Holden S, et al. Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: A prospective study using T2* cardiovascular magnetic resonance. Br J Haematol 2004; 127: 348-355.
24. Noetzli LJ, Carson SM, Nord AS, et al. Longitudinal analysis of heart and liver iron in thalassemia major. Blood 2008; 112: 2973-2978.
25. Wood JC, Enriquez C, Ghugre N, et al. MRI R2 and R2* mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients. Blood 2005; 106: 1460-1465.
26. Ghugre NR, Enriquez CM, Coates TD, et al. Improved R2* measurements in myocardial iron overload. J Magn Reson Imaging 2006; 23: 9-16.
27. Noetzli LJ, Papudesi J, Coates TD, et al. Pancreatic iron loading predicts cardiac iron loading in thalassemia major. Blood 2009; 114: 4021-4026.
28. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997; 20: 1183-1197.
29. Stumvoll M, Mitrakou A, Pimenta W, et al. Use of the oral glucose tolerance test to assess insulin release and insulin sensitivity. Diabetes Care 2000; 23: 295-301.
30. Caumo A, Bergman RN, Cobelli C. Insulin sensitivity from meal tolerance tests in normal subjects: A minimal model index. J Clin Endocrinol Metab 2000; 85: 4396-4402.
31. Bergman RN, Phillips LS, Cobelli C. Physiologic evaluation of factors controlling glucose tolerance in man: Measurement of insulin sensitivity and beta-cell glucose sensitivity from the response to intravenous glucose. J Clin Invest 1981; 68: 1456-1467.
32. Anderson LJ, Holden S, Davis B, et al. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J 2001; 22: 2171-2179.
33. Farmaki K, Angelopoulos N, Anagnostopoulos G, et al. Effect of enhanced iron chelation therapy on glucose metabolism in patients with beta-thalassaemia major. Br J Haematol 2006; 134: 438-444.
34. Hatunic M, Finucane FM, Norris S, et al. Glucose metabolism after normalization of markers of iron overload by venesection in subjects with hereditary hemochromatosis. Metabolism 2010; 59: 1811-1815.
35. Cutler P. Deferoxamine therapy in high-ferritin diabetes. Diabetes 1989; 38: 1207-1210.
36. Farmaki K, Tzoumari I, Pappa C, et al. Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major. Br J Haematol 2010; 148: 466-475.
37. Bergman RN. Minimal model: Perspective from 2005. Horm Res 2005; 64( Suppl 3): 8-15.
38. Bergman RN, Finegood DT, Kahn SE. The evolution of beta-cell dysfunction and insulin resistance in type 2 diabetes. Eur J Clin Invest 2002; 32( Suppl 3): 35-45.
39. Drews G, Krippeit-Drews P, Dufer M. Oxidative stress and beta-cell dysfunction. Pflugers Arch 2010; 460: 703-718.
40. Cappellini MD, Cohen AR, Eleftheriou A, et al., editors. Guidelines for the clinical management of thalassaemia. Nicosia, Cypress: Thalassemia International Federation; 2008.
41. Vichinsky E, editor. Standards of Care Guidelines for Thalassemia. Oakland, CA: Children's Hospital and Research Center Oakland; 2008.
42. Mooy JM, Grootenhuis PA, de Vries H, et al. Intra-individual variation of glucose, specific insulin and proinsulin concentrations measured by two oral glucose tolerance tests in a general Caucasian population: The Hoorn Study. Diabetologia 1996; 39: 298-305.
43. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: A method for quantifying insulin secretion and resistance. Am J Physiol 1979; 237: E214-E223.
44. Mari A, Pacini G, Murphy E, et al. A model-based method for assessing insulin sensitivity from the oral glucose tolerance test. Diabetes Care 2001; 24: 539-548.